Trade

with

Durata Therapeutics Inc
(NASDAQ: DRTX)
AdChoices
23.82
-0.27
-1.12%
After Hours :
23.82
0.00
0.00%

Open

23.87

Previous Close

24.09

Volume (Avg)

305.75k (594.27k)

Day's Range

23.81-24.06

52Wk Range

8.99-24.33

Market Cap.

637.84M

Dividend Rate ( Yield )

-

Beta

3.96

Shares Outstanding

26.78M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 0

    • Net Income

    • -62.14M

    • Market Cap.

    • 637.84M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 3.96

    • Forward P/E

    • -16.05

    • Price/Sales

    • -

    • Price/Book Value

    • 238.10

    • Price/Cash flow

    • -9.79

      • EBITDA

      • -58.38M

      • Return on Capital %

      • -65.46

      • Return on Equity %

      • -194.03

      • Return on Assets %

      • -65.46

      • Book Value/Share

      • 0.10

      • Shares Outstanding

      • 26.78M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 23.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -1.50

        • Cashflow Estimate

        • -1.25

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 14.30

              • 0.76

              • Current Ratio

              • 3.76

              • 2.92

              • Quick Ratio

              • 3.14

              • 2.35

              • Interest Coverage

              • -18.49

              • 38.02

              • Leverage Ratio

              • 29.12

              • 2.21

              • Book Value/Share

              • 0.10

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -9.81

                • 277.78

                • P/E Ratio 5-Year High

                • -9.91

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.71

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.35

                • Price/Book Value

                • 238.10

                • 8.50

                • Price/Cash Flow Ratio

                • -9.79

                • 50.25

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -194.03

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -65.46

                        (-)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -98.51

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • -

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -56.97M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -9.79
                      Ownership

                      Institutional Ownership

                      93.77%

                      Top 10 Institutions

                      76.12%

                      Mutual Fund Ownership

                      18.05%

                      Float

                      58.33%

                      5% / Insider Ownership

                      0.62%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Oppenheimer Global Opportunities

                      •  

                        1,000,000

                      • 0.00

                      • 3.73

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        720,291

                      • 0.00

                      • 2.69

                      • Vanguard VIF Small Comp Gr

                      •  

                        351,900

                      • 38.94

                      • 1.31

                      • iShares Russell 2000 (AU)

                      •  

                        243,458

                      • -1.01

                      • 1.70

                      • Vanguard US Discoveries Fund

                      •  

                        203,899

                      • -2.25

                      • 0.76

                      • Vanguard Total Stock Mkt Idx

                      •  

                        201,930

                      • 0.00

                      • 0.75

                      • Hartford Small Cap Growth HLS Fund

                      •  

                        177,687

                      • 0.00

                      • 0.66

                      • Hartford SmallCap Growth Fund

                      •  

                        171,580

                      • 12.93

                      • 0.64

                      • Northwestern Mutual Ser Sm Cp Gr Stk

                      •  

                        138,790

                      • 0.00

                      • 0.52

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        129,737

                      • 0.00

                      • 0.48

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Domain Associates, LLC

                      •  

                        3,034,688

                      • 0.00%

                      • 11.39

                      • New Leaf Ventures II LP

                      •  

                        3,028,439

                      • 0.00%

                      • 11.37

                      • Aisling Capital Partners III LLC

                      •  

                        2,280,175

                      • -24.75%

                      • 8.56

                      • Aisling Capital LLC

                      •  

                        2,030,175

                      • -33.00%

                      • 7.58

                      • Wellington Management Company, LLP

                      •  

                        1,942,397

                      • +3.14%

                      • 7.25

                      • Orbimed Advisors, LLC

                      •  

                        1,785,714

                      • 0.00%

                      • 6.67

                      • Sofinnova Management VII, L.L.C.

                      •  

                        1,777,856

                      • -21.73%

                      • 6.67

                      • Quaker BioVentures Capital II, LLC

                      •  

                        1,533,333

                      • +15.00%

                      • 5.76

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

                      Key People

                      Mr. Paul R. Edick

                      CEO/Director/President

                      Mr. Corey N. Fishman

                      CFO/Chief Accounting Officer/COO

                      Wendy L. Yarno

                      Director

                      Nicole Vitullo

                      Director

                      Mr. Brenton K. Ahrens

                      Director

                      • Durata Therapeutics Inc

                      • 200 South Wacker Drive

                      • Chicago, IL 60606

                      • USA.Map

                      • Phone: +1 312 219-7000

                      • Fax: -

                      • duratatherapeutics.com

                      Incorporated

                      2009

                      Employees

                      68

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: